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A 45-year-old female was diagnosed as having lung adenocarcinoma harboring an anaplastic lymphoma kinase
(ALK) rearrangement, stage IV (T2bN3M1b). She was treated with crizotinib as second-line chemotherapy. The clinical
stage after crizotinib treatment was ycT2aN0M0, stage IB. We performed a left lower lobectomy and lymph node
dissection aimed at local control and pathological confirmation of the remaining tumor. The final pathological
stage was ypT2aN2M0, stage IIIA with Ef 1b. To the best of our knowledge, this is the first case report of surgical
resection in ALK rearrangement-positive lung adenocarcinoma after crizotinib treatment.
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Rearrangements of the ALK gene are present in 3% to
5% of non-small cell lung cancers (NSCLCs) [1,2]. They
define a distinct subgroup of NSCLC that typically oc-
curs in younger patients who have never smoked or have
a history of light smoking and that has adenocarcinoma
histologic characteristics [3-5].
Crizotinib is an oral small-molecule tyrosine kinase
inhibitor (TKI) of ALK, MET, and ROS1 kinases [6]. Cri-
zotinib competes with adenosine triphosphate for bind-
ing to the tyrosine kinase pocket of ALK and thereby
inhibits its tyrosine kinase activity, leading to inhibition
of downstream signaling and to anticancer effects.
In phase 1 and 2 studies, crizotinib treatment resulted
in objective tumor responses in approximately 60% of pa-
tients with ALK-positive NSCLC and in progression-free
survival of 7 to 10 months [7-9]. In a randomized phase
3 trial involving patients with advanced ALK-positive
NSCLC who had received previous platinum-based
chemotherapy, crizotinib was superior to single-agent
second-line chemotherapy with either pemetrexed or
docetaxel [10]. And also in a randomized phase 3 trial
involving patients with previously untreated advanced
ALK-positive NSCLC, crizotinib was superior to standard
first-line pemetrexed-plus-platinum chemotherapy [11].* Correspondence: w-ken1@muj.biglobe.ne.jp
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tive crizotinib treatment in NSCLC patients. We report
the case of a 45-year-old female who underwent surgical
resection after crizotinib treatment in stage IV NSCLC.Case presentation
A 45-year-old female, current smoker with no significant
medical history, was found to have a left lung mass in July
2012. Chest computed tomography (CT) revealed a 58-
mm-diameter mass in the left lower lobe and bilateral
hilar and mediastinal lymphadenopathy. Positron emission
tomography (PET)-CT showed FDG accumulation in the
lesions mentioned above and in the left axillary lymph
node. The serum carcinoembryonic antigen (CEA) level
was high as 71.0 ng/ml. Transbronchial biopsy of the
primary lesion revealed adenocarcinoma. Head mag-
netic resonance imaging (MRI) was negative for metas-
tases. The clinical stage was determined based on the
TNM Classification of the International Union Against
Cancer (UICC), 7th edition, and the patient was consid-
ered to have inoperable T2bN3M1b. stage IV disease. We
evaluated the responsiveness of tumor to chemotherapy,
based on Response Evaluation Criteria in Solid Tumors
(RECIST), version 1.1.
In August 2012, chemotherapy with cisplatin and peme-
trexed was initiated, resulting in stable disease after four
courses, followed by seven cycles of pemetrexed continu-
ation maintenance therapy. Although she achieved stableThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Chest CT and PET-CT images before and after
crizotinib treatment. (A) Chest CT and PET-CT before treatment
revealing a large primary lung mass (arrowhead) and multiple
lymph node metastases affecting mediastinal and bilateral hilar
lymph nodes (arrow). (B) Chest CT and PET-CT 6 months after
initiation of crizotinib therapy showing significantly decreased
tumor and no FDG accumulation in the primary and other lesions.
Figure 2 Representative images of immunohistochemical staining and
showed moderate ALK protein expression. (B) Fluorescent in situ hybridization
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curred at the right mediastinal lymph nodes (Figure 1A).
Immunohistochemistry (IHC) and fluorescent in situ
hybridization (FISH) revealed that the tumor had an ALK
rearrangement (Figure 2A,B). Crizotinib (250 mg twice
daily), started in June 2013, produced a favorable response;
chest CT showed marked decreases of the primary lesion
and lymph nodes. PET-CT showed no FDG accumulation
in the primary and other lesions (Figure 1B). A partial re-
sponse was achieved and maintained for 6 months by cri-
zotinib treatment. The clinical stage after crizotinib
treatment was ycT2aN0M0, stage IB: 1) the serum CEA
level decreased to 7.4 ng/ml once and increased slightly
afterwards, 2) there is a possibility of tumor progression
because of progression-free survival of crizotinib treat-
ment, and 3) the patient’s hope for surgical resection of re-
sidual tumor was the reason for considering salvage
surgery. Surgery for local control and pathological con-
firmation of the remaining tumor was performed with the
patient’s consent. In December 2013, a left lower lobec-
tomy and lymph node dissection were performed. Intraop-
erative findings showed rigid fibrosis surrounding the
hilum of the lower lobe, considered to be a scar of a meta-
static lymph node after crizotinib treatment. The oper-
ation took 4 h and 23 min, with blood loss of 200 ml. No
blood transfusion was needed. The final pathological stage
was ypT2aN2M0, stage IIIA with Ef 1b. The postoperative
course was uneventful, and the patient was discharged on
the eight postoperative day. The patient was free of disease
6 months after surgery.
Discussion
Recently, several authors reported surgical treatment,
which can be performed for local control and diagnostic
intent after epidermal growth factor receptor (EGFR)-
TKI gefitinib administration, showing long-term survival
in some patients [12,13]. And the strategy of salvage sur-
gery for super responder of targeted therapy seemed to
be worth exploring.
Crizotinib is an oral small-molecule TKI targeting
ALK. The present patient with ALK rearrangement-fluorescent in situ hybridization for ALK. (A) Immunohistochemistry
analysis showed translocation of the ALK gene.
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of tumor only 6 months after starting crizotinib. Despite
the remarkable downstaging after crizotinib treatment, the
patient had a more advanced pathological stage than the
preoperative clinical stage. Dramatic radiologic response
does not necessarily correlate with cell death. The present
result suggests initially expressed systemic disease was es-
sentially unchanged even after dramatic radiologic re-
sponse to crizotinib. Stage IV lung cancer is considered to
be a systemic disease; therefore, surgical treatment is
rarely viewed as a feasible option. Nevertheless, some re-
ports indicate near-complete pathological response of ad-
vanced NSCLC after induction chemotherapy [12,14].
Systemic preoperative therapy is increasingly used in ad-
vanced NSCLC in order to downstage the disease, reduce
the burden of distant micrometastases, and thus provide
an opportunity for potentially curative resection. To the
best of our knowledge, this is the first case report of surgi-
cal resection in ALK rearrangement-positive lung adeno-
carcinoma after crizotinib treatment.
Conclusions
We report a case of surgical resection of lung adenocar-
cinoma after crizotinib treatment. The present report pro-
vides insight into the efficacy of surgery after crizotinib
therapy, but a prospective study is needed to verify this
and the optimal duration of ALK-TKI treatment, the
timing of surgery, and the role of adjuvant ALK-TKI
treatment.
Consent
Written informed consent was obtained from the patient
for the publication of this case presentation and accom-
panying images. A copy of the written consent is avail-
able for the review by the Editor-in-Chief of this journal.
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